Annovis Bio (ANVS) Common Equity (2019 - 2026)
Annovis Bio (ANVS) posted Common Equity of $3.1 million for Q1 2026, down 81.45% sequentially from $16.9 million in Q4 2025, and down 87.0% YoY from $24.1 million in Q1 2025.
Annovis Bio (ANVS) Common Equity (2019 - 2026) Analysis & Trends
Annovis Bio has reported Common Equity for 8 years, with the latest figure at $3.1 million in Q1 2026.
- Quarterly Common Equity fell 87.0% year-over-year to $3.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $3.1 million (down 87.0% YoY) and the FY2025 annual result came in at $16.9 million, up 81.05% from the prior year.
- Common Equity fell to $3.1 million in Q1 2026 per ANVS's latest filing, from $16.9 million in the prior quarter.
- Over five years, Common Equity peaked at $42.7 million in Q1 2022 and troughed at -$7.8 million in Q4 2023.
- A 5-year average of $15.9 million and a median of $16.9 million in 2025 frame the typical range for Common Equity.
- The sharpest annual moves came in 2023 and 2025: Common Equity sank 127.37% in 2023, then soared 1146.93% in 2025.
- Over 5 years, Common Equity stood at $28.3 million in 2022, then tumbled by 127.37% to -$7.8 million in 2023, then surged by 220.09% to $9.3 million in 2024, then jumped by 81.05% to $16.9 million in 2025, then sank by 81.45% to $3.1 million in 2026.
- According to Business Quant data, Common Equity over the past three periods registered $3.1 million, $16.9 million, and $13.2 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 20.25 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 31.71 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 6.76 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 5.17 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 1.35 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 757.49 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 9.79 Bn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 22.38 Bn |
| 10 | Annovis Bio | 66.78 Mn | 66.78 Mn | - | -4.25 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 3.13 Mn |
| Dec 31, 2025 | 16.85 Mn |
| Sep 30, 2025 | 13.16 Mn |
| Jun 30, 2025 | 18.33 Mn |
| Mar 31, 2025 | 24.05 Mn |
| Dec 31, 2024 | 9.31 Mn |
| Sep 30, 2024 | 7.06 Mn |
| Jun 30, 2024 | -1.75 Mn |
| Mar 31, 2024 | -3.35 Mn |
| Dec 31, 2023 | -7.75 Mn |
| Sep 30, 2023 | 6.66 Mn |
| Jun 30, 2023 | 20.74 Mn |
| Mar 31, 2023 | 20.14 Mn |
| Dec 31, 2022 | 28.32 Mn |
| Sep 30, 2022 | 34.59 Mn |
| Jun 30, 2022 | 38.67 Mn |
| Mar 31, 2022 | 42.70 Mn |
| Dec 31, 2021 | 44.49 Mn |
| Sep 30, 2021 | 46.53 Mn |
| Jun 30, 2021 | 48.61 Mn |